Biocon has informed that Biocon Pharma, a wholly owned subsidiary of the Company, has received approval from the U.S Food and Drug Administration (U.S. FDA) for its ANDA Norepinephrine Bitartrate Injection USP, 4 mg/4 mL (1 mg/mL) single-dose vial. Norepinephrine bitartrate injection is indicated to raise blood pressure in adult patients with acute hypotension. The approval further adds to Biocon’s portfolio of complex drug products. The above information will also be available on the website of the Company at www.biocon.com.
The above information is a part of company’s filings submitted to BSE.
